|Bid||63.69 x 1200|
|Ask||75.00 x 900|
|Day's Range||59.94 - 63.84|
|52 Week Range||23.17 - 68.00|
|Beta (5Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 27, 2021 - May 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.14|
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31st Annual Healthcare Conference.
ATRC earnings call for the period ending December 31, 2020.
Shares of AtriCure (NASDAQ:ATRC) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 51.35% year over year to ($0.18), which beat the estimate of ($0.28). Revenue of $57,725,000 declined by 5.86% from the same period last year, which missed the estimate of $58,100,000. Guidance Atricure Sees FY21 Adj. EBITDA Loss $10M, Adj. EPS $(1.15), Sales ~$250M Atricure Sees Q1 Sales $55M-$57M vs $59.3M Estimate, Adj. EPS $(0.39)-$(0.36) Conference Call Details Date: Feb 23, 2021 Time: 04:30 PM View more earnings on ATRC ET Webcast URL: https://edge.media-server.com/mmc/p/7888agea Technicals 52-week high: $67.01 52-week low: $23.16 Price action over last quarter: Up 69.55% Company Overview AtriCure Inc an atrial fibrillation solutions company that provides products, professional education, and support for clinical science to reduce the economic and social burden of atrial fibrillation. Its products line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offer a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021Earnings Preview: AtriCure© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.